A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

ClinicalTrials.gov ID: NCT00735085

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00735085. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Randomized, Double Blind, Placebo Controlled, Phase 2 Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple I.V. Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic Brain Injury.

Study identification

NCT ID: NCT00735085
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Abbott Products; Industry
Enrollment: 57 participants

Conditions and interventions

Conditions

Traumatic Brain Injury

Interventions

SLV334 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 16 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2009 (Type not available)
Primary completion: Aug 2010 (Actual)
Completion: Aug 2010 (Actual)
Last update posted: Sep 21, 2011

2009 – 2010

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
Site Reference ID/Investigator# 45771	Baltimore	Maryland	21201	—
Site Reference ID/Investigator# 45775	Dayton	Ohio	45409	—
Site Reference ID/Investigator# 45770	Portland	Oregon	97232	—
Site Reference ID/Investigator# 45785	Pittsburgh	Pennsylvania	15212	—
Site Reference ID/Investigator# 45780	Pittsburgh	Pennsylvania	15213	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00735085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2011 · Synced Nov 14, 2026